CARM (CARISMA Therapeutics) Total Inventories: $0.00 Mil (As of Sep. 2025)


What is CARISMA Therapeutics Total Inventories?

CARISMA Therapeutics CARM +1.25% Total Inventories is $0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's total inventories for the quarter that ended in Sep. 2025 was $0.00 Mil. CARISMA Therapeutics's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Sep. 2025 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CARISMA Therapeutics's Net-Net Working Capital per share for the quarter that ended in Sep. 2025 was $-0.11.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CARISMA Therapeutics's Inventory-to-Revenue for the quarter that ended in Sep. 2025 was 0.00.

CARISMA Therapeutics  (OTCPK:CARM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

CARISMA Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2025 is

Net-Net Working Capital Per Share (Q: Sep. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(2.777+0.75 * 0+0.5 * 0-7.421
-0-0)/41.788
=-0.11

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CARISMA Therapeutics's Days Inventory for the three months ended in Sep. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2025 )/Cost of Goods Sold (Q: Sep. 2025 )*Days in Period
=0/0*365 / 4
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

CARISMA Therapeutics's Inventory Turnover for the quarter that ended in Sep. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2025 ) / Average Total Inventories (Q: Sep. 2025 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CARISMA Therapeutics's Inventory to Revenue for the quarter that ended in Sep. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2025 ) / Revenue (Q: Sep. 2025 )
=0 / 45.25
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

CARISMA Therapeutics Total Inventories Related Terms

CARISMA Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Total Inventories Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Inventories
0.00 0.00 0.00 0.00 0.00

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CARISMA Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of $0.00 Mil mean?
CARISMA Therapeutics (CARM) has a Total Inventories of $0.00 Mil as of Sep. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Total Inventories too high?
CARISMA Therapeutics' current Total Inventories is $0.00 Mil.
How does CARISMA Therapeutics' Total Inventories compare to VRTX and REGN?
CARISMA Therapeutics' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Total Inventories is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.